Navigation Links
RUB researchers find over active enzyme in failing hearts
Date:1/17/2013

A certain enzyme, the CaM kinase II, keeps the cardiac muscle flexible. By transferring phosphate groups to the giant protein titin, it relaxes the muscle cells. This is reported by researchers led by Prof. Dr. Wolfgang Linke of the Institute of Physiology at the Ruhr Universitt in the journal Circulation Research. In failing hearts, which don't pump enough blood around the body, the scientists found an overly active CaM kinase II. "The phosphorylation of titin could be a new starting point for the treatment of heart failure" Prof. Linke speculates.

Titin phosphorylation determines the mechanical tension of the muscle cell

Titin is the largest protein in the human body, and it acts like a spring which tenses or relaxes the muscle cell. The attachment of phosphate groups to specific titin sites - known as phosphorylation - relaxes the cell. It was already known that the calcium/calmodulin-dependent kinase II, CaM kinase II for short, phosphorylates several proteins in heart cells. Whether it also targets the spring protein titin, has now been examined by the researchers in Bochum.

CaM-Kinase II phosphorylates the giant protein titin

For the study, the researchers used heart cells of "normal" mice, mice that have no CaM kinase II, and mice that produce more CaM kinase II than usual. In cells without the enzyme, titin phosphorylation was reduced by more than 50 percent compared to the normal state. In cells with excess enzyme, however, titin phosphorylation was twice as strong as in normal cells. The CaM kinase II is therefore crucial for the attachment of phosphate groups to the giant protein titin. Linke's team identified two regions within the flexible segment of the titin molecule which are phosphorylated by the enzyme, namely the PEVK and N2Bus region. These sites contain several amino acids of the type serine and threonine, which have changed little in the course of evolution.

The work of the CaM kinase II determines cell stiffness

In further analyses, the research team also showed that a lack or an excess of CaM kinase II affected the stiffness of the muscle cells. Cells without the enzyme were stiffer, cells with the enzyme more flexible. If they added CaM kinase II to cells that were not able to produce the enzyme themselves, these relaxed. In failing human hearts, the team found increased activity of CaM kinase II in comparison with healthy hearts, and thus excessive phosphorylation in the PEVK and N2Bus titin regions. "This seems to alter the mechanical properties of the human heart muscle", says Wolfgang Linke.


'/>"/>

Contact: Wolfgang Linke
wolfgang.linke@rub.de
49-234-322-9101
Ruhr-University Bochum
Source:Eurekalert

Related biology news :

1. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
2. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
3. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
4. UNH researchers find African farmers need better climate change data to improve farming practices
5. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
6. Researchers uncover molecular pathway through which common yeast becomes fungal pathogen
7. Researchers print live cells with a standard inkjet printer
8. Columbia Engineering and Penn researchers increase speed of single-molecule measurements
9. Researchers reveal how a single gene mutation leads to uncontrolled obesity
10. Researchers discover novel therapy for Crohns disease
11. New paper by Notre Dame researchers describes method for cleaning up nuclear waste
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/31/2016)... R.I. , March 31, 2016  Genomics firm ... of founding CEO, Barrett Bready , M.D., who ... members of the original technical leadership team, including Chief ... President of Product Development, Steve Nurnberg and Vice President ... returned to the company. Dr. Bready served ...
(Date:3/23/2016)... March 23, 2016 ... Sicherheit Gesichts- und Stimmerkennung mit Passwörtern ... (NASDAQ: MESG ), ein führender Anbieter ... Unternehmen mit SpeechPro zusammenarbeitet, um erstmals dessen ... wird die Möglichkeit angeboten, im Rahmen mobiler ...
(Date:3/22/2016)... Ontario , PROVO and ... Newborn Screening Ontario (NSO), which operates the ... for molecular testing, and Tute Genomics and UNIConnect, ... management technology respectively, today announced the launch of a ... next-generation sequencing (NGS) testing panel. NSO ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and fluorometers ... the 6000i models are higher end machines that use the more unconventional z-dimension of ... beam from the bottom of the cuvette holder. , FireflySci has developed several ...
(Date:6/23/2016)... 2016 /PRNewswire/ - FACIT has announced the creation ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" or "the ... a portfolio of first-in-class WDR5 inhibitors for the ... WDR5 represent an exciting class of therapies, possessing ... for cancer patients. Substantial advances have been achieved ...
(Date:6/23/2016)... 2016  The Biodesign Challenge (BDC), a university competition ... harness living systems and biotechnology, announced its winning teams ... New York City . The ... projects at MoMA,s Celeste Bartos Theater during the daylong ... senior curator of architecture and design, and Suzanne ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
Breaking Biology Technology: